Patents by Inventor Burghardt Wittig

Burghardt Wittig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10006032
    Abstract: The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: June 26, 2018
    Assignee: Mologen AG
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Burghardt Wittig
  • Publication number: 20160348114
    Abstract: The present invention relates to a covalently closed DNA construct, a pharmaceutical composition and a vaccine and their use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising a specific DNA sequence.
    Type: Application
    Filed: February 18, 2015
    Publication date: December 1, 2016
    Inventors: Christiane Kleuss, Kerstin Kapp, Burghardt Wittig, Matthias Schroff
  • Patent number: 9499815
    Abstract: The invention relates to a multimeric non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, and to a preparation process therefore and a vaccine which comprises the multimeric non-coding nucleic acid molecule.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: November 22, 2016
    Assignee: Mologen AG
    Inventors: Matthias Schroff, Burghardt Wittig, Manuel Schmidt, Janine Loehr
  • Patent number: 9345754
    Abstract: A vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of defined tumor diseases, and a method for the making of such vaccine is disclosed. The tumor cells were previously transfected ex vivo with expression constructs encoding cytokines and co-stimulatory factors.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: May 24, 2016
    Assignee: Mologen AG
    Inventors: Tomislav Dobric, Burghardt Wittig, Manuel Schmidt
  • Publication number: 20160115479
    Abstract: The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.
    Type: Application
    Filed: May 15, 2014
    Publication date: April 28, 2016
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Burghardt Wittig
  • Patent number: 9212366
    Abstract: The invention relates to the use of immune modulators on the basis of DNA in the form of covalently closed nucleic acid molecules comprising immune stimulatory sequence motifs, for the production of a pharmaceutical for the therapeutic treatment of tumor diseases in combination with chemotherapeutic drugs.
    Type: Grant
    Filed: August 9, 2005
    Date of Patent: December 15, 2015
    Assignee: Mologen AG
    Inventors: Burghardt Wittig, Manuel Schmidt, Heribert Bohlen
  • Patent number: 8669100
    Abstract: The invention relates to using a combination of DNA-expression constructs for producing a drug for immunization against leishmania infections and a corresponding vaccine. The DNA-expression construct is also disclosed. According to said invention the immunogene P36 LACK is used in combination with a leishmania infantum thiol-specific antioxidant protein gene (TSA), leishmania infantum kinetoplastid membrane protein 11 (KMP-11) and with a leishmania infantum GP63 antigen for producing an immune response. Plasmides, preferably minimalist immunologically defined gene-expression constructs (MIDGE) can be used in the form of the DNA-expression construct. The inventive DNA-expression construct makes it possible to produce a vaccine for treating leishmania infectious diseases and is used in the form of a component of said vaccine.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: March 11, 2014
    Assignee: Mologen AG
    Inventors: Burghardt Wittig, Laura Fuertes-López, Marcos Timón-Jiménez
  • Publication number: 20120093804
    Abstract: The invention relates to a polymeric, non-coding nucleic acid molecule for modulation of the activity of the human and animal immune system as well as a method for the manufacture thereof and a vaccine, comprising the polymeric, non-coding nucleic acid molecule, wherein polymeric, non-coding nucleic acid molecules may be understood as non-coding nucleic acid molecules, comprising at least four covalently bound molecules (tetramer) or are assemblies of more non-coding nucleic acid molecules (high molecular polymers) which are covalently bound to each other.
    Type: Application
    Filed: April 30, 2010
    Publication date: April 19, 2012
    Applicant: Mologen AG
    Inventors: Matthias Schroff, Burghardt Wittig, Manuel Schmidt, Christiane Kleuss
  • Publication number: 20110223189
    Abstract: The invention relates to using a combination of DNA-expression constructs for producing a drug for immunisation against leishmania infections and a corresponding vaccine. The DNA-expression construct is also disclosed. According to said invention the immunogene P36 LACK is used in combination with a leishmania infantum thiol-specific antioxidant protein gene (TSA), leishmania infantum kinetoplastid membrane protein 11 (KMP-11) and with a leishmania infantum GP63 antigen for producing an immune response. Plasmides, preferably minimalist immunologically defined gene-expression constructs (MIDGE) can be used in the form of the DNA-expression construct. The inventive DNA-expression construct makes it possible to produce a vaccine for treating leishmania infectious diseases and is used in the form of a component of said vaccine.
    Type: Application
    Filed: July 22, 2010
    Publication date: September 15, 2011
    Applicant: MOLOGEN AG
    Inventors: BURGHARDT WITTIG, LAURA FUERTES-LÓPEZ, MARCOS TIMÓN-JIMÉNEZ
  • Patent number: 8017591
    Abstract: Short deoxyribonucleic acid molecules that are partially single-stranded, dumbbell shaped, and covalently closed, which contain one or more unmethylated cytosine guanosine motif (CpG motif) and exhibit immunomodifying effects. Such molecules can be used for immunostimulation applications in humans and vertebrates.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: September 13, 2011
    Assignee: Mològen AG
    Inventors: Bernadette Brzezicha, Christiane Juhls, Florian Sack, Manuel Schmidt, Burghardt Wittig, Matthias Schroff
  • Publication number: 20100303803
    Abstract: The invention relates to a multimeric, non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, and to a production method therefor, and to a vaccine containing said multimeric, non-coding nucleic acid molecule. Said multimeric, non-coding nucleic acid molecules can be non-coding nucleic acid molecules that consist of at least two of said molecules (dimer) or assemblies of several non-coding nucleic acid molecules.
    Type: Application
    Filed: November 7, 2008
    Publication date: December 2, 2010
    Applicant: Mologen AG
    Inventors: Matthias Schroff, Burghardt Wittig, Manuel Schmidt, Janine Löhr, Christiane Kleuss
  • Publication number: 20100297189
    Abstract: Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.
    Type: Application
    Filed: November 9, 2009
    Publication date: November 25, 2010
    Applicant: Mologen AG
    Inventors: Tomislav Dobric, Burghardt Wittig, Manuel Schmidt
  • Patent number: 7795406
    Abstract: Use of a combination of DNA expression constructs for the production of a remedy for the immunization against infections with leishmaniasis, as well as a corresponding vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: September 14, 2010
    Assignee: Mologen AG
    Inventors: Burghardt Wittig, Laura Fuertes-López, Marcos Timón-Jiménez
  • Patent number: 7635468
    Abstract: Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: December 22, 2009
    Assignee: Mologen AG
    Inventors: Tomislav Dobric, Burghardt Wittig, Manuel Schmidt
  • Publication number: 20090220931
    Abstract: The invention relates to a method for the in vitro investigation of the effect of substances in in vivo processes and an in vitro detection method for the identification of immunomodulating compounds and/or the detection of the effect of immunomodulating compounds and the identification of apoptosis-inducing and/or necrosis-inducing compounds mediated by the immune system in in vivo processes. The methods according to the invention are particularly suitable for investigating effects of substances on cells, which are mediated by the immune system. Furthermore, the method according to the invention is suitable for in vitro monitoring of the in vivo effects before, during and/or after the administration of immunomodulating compounds and of apoptosis-inducing and/or necrosis-inducing compounds.
    Type: Application
    Filed: September 8, 2006
    Publication date: September 3, 2009
    Applicant: Mologen AG
    Inventors: Manuel Schmidt, Burghardt Wittig, Astrid Sander, Yiyou Chen
  • Publication number: 20090053250
    Abstract: The invention relates to the use of immune modulators on the basis of DNA in the form of covalently closed nucleic acid molecules comprising immune stimulatory sequence motifs, for the production of a pharmaceutical for the therapeutic treatment of tumor diseases in combination with chemotherapeutic drugs.
    Type: Application
    Filed: August 9, 2005
    Publication date: February 26, 2009
    Applicant: MOLOGEN AG
    Inventors: Burghardt Wittig, Manuel Schmidt, Heribert Bohlen
  • Publication number: 20070160587
    Abstract: Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.
    Type: Application
    Filed: June 30, 2006
    Publication date: July 12, 2007
    Inventors: Tomislav Dobric, Burghardt Wittig, Manuel Schmidt
  • Publication number: 20070049546
    Abstract: A substituted, non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, a method for the production thereof, and a vaccine containing said substituted, non-coding nucleic acid molecule. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.
    Type: Application
    Filed: August 18, 2006
    Publication date: March 1, 2007
    Inventors: Bernadette Brzezicha, Christiane Juhls, Florian Sack, Manuel Schmidt, Burghardt Wittig, Matthias Schroff
  • Publication number: 20060194753
    Abstract: Use of a combination of DNA expression constructs for the production of a remedy for the immunization against infections with leishmaniasis, as well as a corresponding vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.
    Type: Application
    Filed: November 30, 2005
    Publication date: August 31, 2006
    Inventors: Burghardt Wittig, Laura Fuertes-Lopez, Marcos Timon-Jimenez
  • Patent number: 7074772
    Abstract: The invention concerns an expressible nucleic acid construct, which contains only the sequence information necessary for expressing a gene for RNA or protein synthesis. Expression constructs of this type can be used in gene therapy and genetic vaccination and avoid many of the risks associated with constructs today. The invention further concerns the possibility of improving the conveying of the construct into cells or tissue by covalent linkage of the construct, for example to particles of peptides.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: July 11, 2006
    Assignee: Mologen AG
    Inventors: Burghardt Wittig, Claas Junghans